The 21st China Association of Clinical Laboratory Practice (CACLP) Conference, held from March 16th to 19th in the vibrant city of Chongqing, served as a pivotal platform for industry leaders to showcase their latest innovations. Among the distinguished exhibitors was Bioer Technology, which made waves with its unveiling of new digital PCR and molecular POCT (Point-of-Care Testing) solutions, marking a significant milestone in the company's commitment to advancing molecular diagnostics.
Since its inception, Bioer Technology has been deeply entrenched in the field of molecular diagnostics, offering comprehensive solutions ranging from instruments and reagents to consumables. The company's diverse portfolio includes fully automated nucleic acid extractors, fluorescence quantitative PCR instruments, digital PCR systems, and molecular POCT devices. In the realm of reagents, Bioer Technology covers a wide spectrum, providing extraction reagent kits, molecular testing reagents across various domains, and immunogold reagents. Complementing these offerings are consumables tailored for molecular testing and cell culture.
With a steadfast dedication to providing comprehensive guidance to its customers, Bioer Technology ensures that every aspect of molecular diagnostics is addressed effectively. This commitment underscores the company's mission to empower healthcare professionals with the tools they need to deliver accurate and timely diagnoses.
Looking ahead, Bioer Technology remains poised to drive forward in the field of molecular diagnostics, consistently staying at the forefront of industry advancements. With a focus on innovation and customer-centric solutions, the company continues to strengthen its position as a leader in the molecular diagnostic landscape, demonstrating unwavering dedication to improving healthcare outcomes through cutting-edge technology and comprehensive support.